Johnson & Johnson (JNJ) 100.98 $JNJ
Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - 2 hrs 37 mins ago
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial
The Dow's Top 3 Stocks of 2014
Travis Hoium, The Motley Fool - Motley Fool - Mon May 26, 5:03PM CDT
After a banner year in 2013, this year has been less remarkable for the Dow Jones Industrial Average and the stock market in general. Last year's market was driven by multiple expansion, not earnings growth, and earnings now are just trying to...
Cardiovascular Devices - Growth Opportunities In Emerging Markets
M2 - Mon May 26, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94l67n/cardiovascular) has announced the addition of the "Cardiovascular Devices - Growth Opportunities In Emerging Markets" report to their offering. A timely and unique growth opportunity exists for cardiovascular device manufacturers seeking to offset some of the tepid or declining growth they have been experiencing in the US and Western European markets. As a result, multinational cardiovascular device companies have been increasing their investments in emerging nations - and they are reaping the rewards, with demand for some cardiovascular devices increasing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey. Combined, these five emerging countries performed an estimated 2.2 million cardiovascular procedures in 2013 - including interventional cardiology procedures, cardiothoracic surgeries (eg, CABG surgery, heart valve procedures, congenital heart disease procedures, and procedures for aortic aneurysms), and cardiac rhythm management procedures (eg, pacemaker/defibrillator implantations and cardiac ablations) - and that number is projected to increase to more than 3.5 million by 2017, a compound annual growth rate of about 13%. China alone is responsible for nearly 60% of that total (about 1.3 million procedures in 2013) and also offers the highest growth rate of the five over the forecast period (16.8%). This dynamic, new report offers a detailed look at the most promising future growth opportunities for cardiovascular device companies in the BRIC nations and Turkey. Included are analyses and comparisons of cardiovascular procedure volumes, growth rates, and market drivers/limiters for each country covered. The report also provides an overview of multinational cardiovascular device company strategies for penetrating these markets as well as an assessment of next-generation technologies, including "leadless" pacemakers and defibrillators and bioresorbable coronary stents, and their potential to further expand growth in emerging market regions. Key Topics Covered: - Market Overview - Coronary Revascularization - Cardiac Rhythm Management Procedures - Heart Valve Procedures - Cardiovascular Device Opportunities In Emerging Markets, By Country - Multinationals Look To Emerging Markets For Growth - Impact Of New Technologies In Emerging Markets Companies Mentioned - Abbott Laboratories - Abbott Vascular - Apollo Hospitals Enterprise Ltd. - Biosense Webster/Johnson & Johnson - Biostar - Boston Scientific - China Kanghui Holdings - Covidien - Edwards Lifesciences - GE Healthcare - LifeTech Scientific Corp. - Medicall Biomedikal AS - Medtronic - Philips Medical - St. Jude Medical - Stryker - Terumo For more information visit http://www.researchandmarkets.com/research/94...iovascular
Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...
Global Coronary Stents (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) Market Report 2014-2019
M2 - Mon May 26, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dp3jcc/coronary_stents) has announced the addition of the "Coronary Stents Market - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report studies the current as well as future prospects of the coronary stents market globally. The market for coronary stents is categorized into three major segments, namely, bare metal stents (BMS), drug eluting stents (DES) and bio-absorbable stents. Each of the market segments has been extensively analyzed on the basis of their commercial existence, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each product type has been provided for the period 2011 to 2019. The report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2013 to 2019, considering 2012 as the base year. The global coronary stents market has been categorized into four geographical regions - North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market sizes and forecasts for each of these regions have been provided for the period 2011 to 2019 along with CAGR (%) for the forecast period 2013 to 2019. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global coronary stents market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter's five forces analysis and key players' market share analysis in 2012 for the global coronary stents market. A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report also comprises a section on pipeline overview for this market that includes qualitative analysis for various coronary stents currently under phase II, III & IV clinical trials, which are expected to be launched during the forecast period. The global coronary stents market is segmented as follows: Coronary Stents Market, by Product Type - Bare Metal Stents - Drug Eluting Stents - Bio-absorbable Stents Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Coronary Stents Market Overview Chapter 4 Global Coronary Stents Market, by Product Type Chapter 5 Global Coronary Stents Market: Pipeline Overview Chapter 6 Global Coronary Stents Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - amg International GmbH - B. Braun Melsungen AG - Biotronik SE & Co. KG - Boston Scientific Corporation - C. R. Bard, Inc. - Cook Medical, Inc. - Johnson & Johnson - Medtronic, Inc. - MicroPort Scientific Corporation - STENTYS SA - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/dp...ary_stents
Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
M2 - Mon May 26, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6m5p4d/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include - AbbVie Inc. - Galderma S.A. - Johnson & Johnson Ltd. - Novartis AG - Stiefel Laboratories Inc. - Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are - Actavis plc - Allergan Inc. - Almirall SA - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc - Bayer AG - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - Genentech Inc. - Incyte Corp. - Isotechnika Inc. - LEO Pharma A/S - Merck & Co. Inc. - Mylan Pharmaceuticals Inc. - Pfizer Inc. - UCB SA. Key questions answered in this report: - What will the market size and growth rate be in 2018? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? For more information visit http://www.researchandmarkets.com/research/6m5p4d/global
3 Breakthrough Drugs Yield 1 Instant Blockbuster
Todd Campbell, The Motley Fool - Motley Fool - Sat May 24, 10:43AM CDT
The FDA approved 27 new drugs in 2013, including three drugs that were approved under the FDA's breakthrough therapy pathway. That pathway was established by the FDA to speed up clinical trials and FDA approval timelines in a bid to get promising new...
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Final Glance: Pharmaceuticals companies
AP - Fri May 23, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri May 23, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Update on Celsion's ThermoDox - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 4:00PM CDT
Celsion (CLSN) received regulatory clearance to initiate the OPTIMA study on ThermoDox.
Midday Glance: Pharmaceuticals companies
AP - Fri May 23, 12:40PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri May 23, 12:40PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Dow Today: Johnson & Johnson (JNJ) Higher
at The Street - Fri May 23, 11:00AM CDT
The Dow component leading the way higher looks to be Johnson & Johnson (NYSE: JNJ ), which is sporting an eight-cent gain to $101.04.
Early Glance: Pharmaceuticals companies
AP - Fri May 23, 9:39AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri May 23, 9:39AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Record World Cup numbers game for FIFA and Brazil
By GRAHAM DUNBAR - AP - Fri May 23, 8:58AM CDT
GENEVA (AP) — The 2014 World Cup is the most valuable, lucrative and expensive in FIFA history.
Selective JAK Inhibitors for Rheumatoid Arthritis
M2 - Fri May 23, 8:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8xkpbw/selective_jak) has announced the addition of the "Selective JAK Inhibitors for Rheumatoid Arthritis" report to their offering. The role of Janus kinases (JAKs) in mediating inflammation and autoimmunity suggested that they would be appropriate targets for intervention in rheumatoid arthritis (RA). JAKs are a family of intracellular, non-receptor protein tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Pfizer's tofacitinib (Xeljanz) was launched in 2012 for patients with moderate to severe RA. The drug is an oral JAK inhibitor with specificity for JAK1 and JAK2 but with residual activity for JAK2 - leading to some significant safety concerns. Safety risks associated with tofacitinib are related to its activity as an immunosuppressant, effects on hematopoietic blood cells, and modulation of cholesterol levels - all important in managing RA. So far tofacitinib's revenues have disappointed. Selective JAK inhibitors, all oral, in current development for RA and described in the report are: - Baricitinib (Incyte Corporation, Eli Lilly) - INCB39110 (Incyte Corporation) - ASP-015K (Astellas, Johnson & Johnson) - GLPG0634 (Galapagos) - ABT-494 (AbbVie) - VX-509 (Vertex) - A next generation oral specific JAK1 or JAK3 inhibitor, with superior efficacy and/or better safety profile than tofacitinib, will have a better chance of capturing significant market share in the second-line >$3 billion TNF inhibitor market. Key Topics Covered: Rheumatoid Arthritis - Disease mechanisms - Role of JAKs in Autoimmunity - Current treatments Tofacitinib (Xeljanz) - Pharmacology - Clinical Efficacy - Clinical Safety - Disappointing sales thus far Second generation JAK inhibitors - Baricitinib (Incyte Corporation and Eli Lilly) - INCB39110 (Incyte Corporation) - ASP-015K (Astellas and JNJ) - GLPG0634 (Galapagos and AbbVie) - ABT-494 (AbbVie) - VX-509 (Vertex) Clinical and regulatory Discussion Regulatory Issues Market opportunity - Comparative Efficacy for JAK Inhibitors Summary opinion - How does the Xeljanz experience inform the development of second generation JAK inhibitors? - How will the second generation JAK inhibitors be differentiated? Companies Mentioned: - AbbVie - Astellas - Eli Lilly - Galapagos - Incyte Corporation - Johnson & Johnson - Pfizer - Vertex For more information visit http://www.researchandmarkets.com/research/8x...ective_jak
Intercept Pharmaceuticals' Obeticholic Acid for Liver Diseases Report
M2 - Fri May 23, 2:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bfcxg8/intercept) has announced the addition of the "Intercept Pharmaceuticals' Obeticholic Acid for liver diseases" report to their offering. Obeticholic acid (OCA) is a derivative of chenodeoxycholic acid, the dominant component of bile. It is a potent stimulator of farnesoid X receptor and in that way differs both from chenodeoxycholic acid and ursodeoxycholic acid (URSO), another bile acid used therapeutically. Intercept is developing OCA for use in a variety of liver diseases. Primary biliary cirrhosis (PBC), an orphan inflammatory disease of bile ducts, is the lead indication. But non-alcoholic steatohepatitis (NASH), a liver disorder that substantively overlaps with the epidemiology and pathophysiology of the metabolic syndrome is close behind. Intercept has also initiated/reported pilot efforts in bile acid diarrhea (BAD), acute alcoholic hepatitis, and portal hypertension. This initiation report explores these programs in depth, including the underlying rationale for use and a review of the phase II data in the lead PBC and NASH indications. It also explores issues related to the later phase trials for those indications, including the selection of endpoints. In PBC and especially in NASH, the ability to identify those who will have poor long-term outcomes (and thus would benefit from therapy) is difficult. Thus, endpoint selection and FDA's acceptance of data showing impact on those measures becomes a central issue when assessing the probabilities of regulatory success. The report also reviews the rationale and available data from the other programs and also looks at the competitive landscapes for each. Key Topics Covered: 1. Primary biliary cirrhosis (PBC) - The disease - Phase II, including long-term extension data (ICPT 2013 10-K) - POISE - Accelerated Approval in PBC and surrogates of transplant-free survival - Will one study be enough? - In summary 2. Non-alcoholic steatohepatitis (NASH) - NAFLD and NASHa brief review - Phase II study in diabetic NAFLD - The FLINT study - Endpoint issues and approval pathways for NASH - Update on lipid changes in phase II studies of fatty liver 3. Update on other indications 4. Summary opinion - PBC - NASH - Other indications Companies Mentioned - Albireo - Antipodean Pharmaceuticals - Intercept Pharmaceuticals - Johnson & Johnson - Kotobuki Pharmaceuticals - NovImmune - Phenex For more information visit http://www.researchandmarkets.com/research/bfcxg8/intercept About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Dow Inches Higher As Travelers Hits New All-Time High; J&J, Pfizer Also Gain
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 22, 8:05PM CDT
On Thursday, the Dow Jones Industrials gained 10 points, lagging behind the percentage gains in the broader market but still adding to its triple-digit advance from Wednesday. Investors seemed content to ride the ongoing wave of optimism higher,...
Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - 2 hrs 37 mins ago
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial
The Dow's Top 3 Stocks of 2014
Travis Hoium, The Motley Fool - Motley Fool - Mon May 26, 5:03PM CDT
After a banner year in 2013, this year has been less remarkable for the Dow Jones Industrial Average and the stock market in general. Last year's market was driven by multiple expansion, not earnings growth, and earnings now are just trying to...
Cardiovascular Devices - Growth Opportunities In Emerging Markets
M2 - Mon May 26, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94l67n/cardiovascular) has announced the addition of the "Cardiovascular Devices - Growth Opportunities In Emerging Markets" report to their offering. A timely and unique growth opportunity exists for cardiovascular device manufacturers seeking to offset some of the tepid or declining growth they have been experiencing in the US and Western European markets. As a result, multinational cardiovascular device companies have been increasing their investments in emerging nations - and they are reaping the rewards, with demand for some cardiovascular devices increasing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey. Combined, these five emerging countries performed an estimated 2.2 million cardiovascular procedures in 2013 - including interventional cardiology procedures, cardiothoracic surgeries (eg, CABG surgery, heart valve procedures, congenital heart disease procedures, and procedures for aortic aneurysms), and cardiac rhythm management procedures (eg, pacemaker/defibrillator implantations and cardiac ablations) - and that number is projected to increase to more than 3.5 million by 2017, a compound annual growth rate of about 13%. China alone is responsible for nearly 60% of that total (about 1.3 million procedures in 2013) and also offers the highest growth rate of the five over the forecast period (16.8%). This dynamic, new report offers a detailed look at the most promising future growth opportunities for cardiovascular device companies in the BRIC nations and Turkey. Included are analyses and comparisons of cardiovascular procedure volumes, growth rates, and market drivers/limiters for each country covered. The report also provides an overview of multinational cardiovascular device company strategies for penetrating these markets as well as an assessment of next-generation technologies, including "leadless" pacemakers and defibrillators and bioresorbable coronary stents, and their potential to further expand growth in emerging market regions. Key Topics Covered: - Market Overview - Coronary Revascularization - Cardiac Rhythm Management Procedures - Heart Valve Procedures - Cardiovascular Device Opportunities In Emerging Markets, By Country - Multinationals Look To Emerging Markets For Growth - Impact Of New Technologies In Emerging Markets Companies Mentioned - Abbott Laboratories - Abbott Vascular - Apollo Hospitals Enterprise Ltd. - Biosense Webster/Johnson & Johnson - Biostar - Boston Scientific - China Kanghui Holdings - Covidien - Edwards Lifesciences - GE Healthcare - LifeTech Scientific Corp. - Medicall Biomedikal AS - Medtronic - Philips Medical - St. Jude Medical - Stryker - Terumo For more information visit http://www.researchandmarkets.com/research/94...iovascular
Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...
Global Coronary Stents (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) Market Report 2014-2019
M2 - Mon May 26, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dp3jcc/coronary_stents) has announced the addition of the "Coronary Stents Market - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report studies the current as well as future prospects of the coronary stents market globally. The market for coronary stents is categorized into three major segments, namely, bare metal stents (BMS), drug eluting stents (DES) and bio-absorbable stents. Each of the market segments has been extensively analyzed on the basis of their commercial existence, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each product type has been provided for the period 2011 to 2019. The report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2013 to 2019, considering 2012 as the base year. The global coronary stents market has been categorized into four geographical regions - North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market sizes and forecasts for each of these regions have been provided for the period 2011 to 2019 along with CAGR (%) for the forecast period 2013 to 2019. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global coronary stents market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter's five forces analysis and key players' market share analysis in 2012 for the global coronary stents market. A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report also comprises a section on pipeline overview for this market that includes qualitative analysis for various coronary stents currently under phase II, III & IV clinical trials, which are expected to be launched during the forecast period. The global coronary stents market is segmented as follows: Coronary Stents Market, by Product Type - Bare Metal Stents - Drug Eluting Stents - Bio-absorbable Stents Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Coronary Stents Market Overview Chapter 4 Global Coronary Stents Market, by Product Type Chapter 5 Global Coronary Stents Market: Pipeline Overview Chapter 6 Global Coronary Stents Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - amg International GmbH - B. Braun Melsungen AG - Biotronik SE & Co. KG - Boston Scientific Corporation - C. R. Bard, Inc. - Cook Medical, Inc. - Johnson & Johnson - Medtronic, Inc. - MicroPort Scientific Corporation - STENTYS SA - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/dp...ary_stents
Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
M2 - Mon May 26, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6m5p4d/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include - AbbVie Inc. - Galderma S.A. - Johnson & Johnson Ltd. - Novartis AG - Stiefel Laboratories Inc. - Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are - Actavis plc - Allergan Inc. - Almirall SA - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc - Bayer AG - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - Genentech Inc. - Incyte Corp. - Isotechnika Inc. - LEO Pharma A/S - Merck & Co. Inc. - Mylan Pharmaceuticals Inc. - Pfizer Inc. - UCB SA. Key questions answered in this report: - What will the market size and growth rate be in 2018? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? For more information visit http://www.researchandmarkets.com/research/6m5p4d/global
3 Breakthrough Drugs Yield 1 Instant Blockbuster
Todd Campbell, The Motley Fool - Motley Fool - Sat May 24, 10:43AM CDT
The FDA approved 27 new drugs in 2013, including three drugs that were approved under the FDA's breakthrough therapy pathway. That pathway was established by the FDA to speed up clinical trials and FDA approval timelines in a bid to get promising new...
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Final Glance: Pharmaceuticals companies
AP - Fri May 23, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri May 23, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Update on Celsion's ThermoDox - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 4:00PM CDT
Celsion (CLSN) received regulatory clearance to initiate the OPTIMA study on ThermoDox.
Midday Glance: Pharmaceuticals companies
AP - Fri May 23, 12:40PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri May 23, 12:40PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Dow Today: Johnson & Johnson (JNJ) Higher
at The Street - Fri May 23, 11:00AM CDT
The Dow component leading the way higher looks to be Johnson & Johnson (NYSE: JNJ ), which is sporting an eight-cent gain to $101.04.
Early Glance: Pharmaceuticals companies
AP - Fri May 23, 9:39AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri May 23, 9:39AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Record World Cup numbers game for FIFA and Brazil
By GRAHAM DUNBAR - AP - Fri May 23, 8:58AM CDT
GENEVA (AP) — The 2014 World Cup is the most valuable, lucrative and expensive in FIFA history.
Selective JAK Inhibitors for Rheumatoid Arthritis
M2 - Fri May 23, 8:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8xkpbw/selective_jak) has announced the addition of the "Selective JAK Inhibitors for Rheumatoid Arthritis" report to their offering. The role of Janus kinases (JAKs) in mediating inflammation and autoimmunity suggested that they would be appropriate targets for intervention in rheumatoid arthritis (RA). JAKs are a family of intracellular, non-receptor protein tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Pfizer's tofacitinib (Xeljanz) was launched in 2012 for patients with moderate to severe RA. The drug is an oral JAK inhibitor with specificity for JAK1 and JAK2 but with residual activity for JAK2 - leading to some significant safety concerns. Safety risks associated with tofacitinib are related to its activity as an immunosuppressant, effects on hematopoietic blood cells, and modulation of cholesterol levels - all important in managing RA. So far tofacitinib's revenues have disappointed. Selective JAK inhibitors, all oral, in current development for RA and described in the report are: - Baricitinib (Incyte Corporation, Eli Lilly) - INCB39110 (Incyte Corporation) - ASP-015K (Astellas, Johnson & Johnson) - GLPG0634 (Galapagos) - ABT-494 (AbbVie) - VX-509 (Vertex) - A next generation oral specific JAK1 or JAK3 inhibitor, with superior efficacy and/or better safety profile than tofacitinib, will have a better chance of capturing significant market share in the second-line >$3 billion TNF inhibitor market. Key Topics Covered: Rheumatoid Arthritis - Disease mechanisms - Role of JAKs in Autoimmunity - Current treatments Tofacitinib (Xeljanz) - Pharmacology - Clinical Efficacy - Clinical Safety - Disappointing sales thus far Second generation JAK inhibitors - Baricitinib (Incyte Corporation and Eli Lilly) - INCB39110 (Incyte Corporation) - ASP-015K (Astellas and JNJ) - GLPG0634 (Galapagos and AbbVie) - ABT-494 (AbbVie) - VX-509 (Vertex) Clinical and regulatory Discussion Regulatory Issues Market opportunity - Comparative Efficacy for JAK Inhibitors Summary opinion - How does the Xeljanz experience inform the development of second generation JAK inhibitors? - How will the second generation JAK inhibitors be differentiated? Companies Mentioned: - AbbVie - Astellas - Eli Lilly - Galapagos - Incyte Corporation - Johnson & Johnson - Pfizer - Vertex For more information visit http://www.researchandmarkets.com/research/8x...ective_jak
Intercept Pharmaceuticals' Obeticholic Acid for Liver Diseases Report
M2 - Fri May 23, 2:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bfcxg8/intercept) has announced the addition of the "Intercept Pharmaceuticals' Obeticholic Acid for liver diseases" report to their offering. Obeticholic acid (OCA) is a derivative of chenodeoxycholic acid, the dominant component of bile. It is a potent stimulator of farnesoid X receptor and in that way differs both from chenodeoxycholic acid and ursodeoxycholic acid (URSO), another bile acid used therapeutically. Intercept is developing OCA for use in a variety of liver diseases. Primary biliary cirrhosis (PBC), an orphan inflammatory disease of bile ducts, is the lead indication. But non-alcoholic steatohepatitis (NASH), a liver disorder that substantively overlaps with the epidemiology and pathophysiology of the metabolic syndrome is close behind. Intercept has also initiated/reported pilot efforts in bile acid diarrhea (BAD), acute alcoholic hepatitis, and portal hypertension. This initiation report explores these programs in depth, including the underlying rationale for use and a review of the phase II data in the lead PBC and NASH indications. It also explores issues related to the later phase trials for those indications, including the selection of endpoints. In PBC and especially in NASH, the ability to identify those who will have poor long-term outcomes (and thus would benefit from therapy) is difficult. Thus, endpoint selection and FDA's acceptance of data showing impact on those measures becomes a central issue when assessing the probabilities of regulatory success. The report also reviews the rationale and available data from the other programs and also looks at the competitive landscapes for each. Key Topics Covered: 1. Primary biliary cirrhosis (PBC) - The disease - Phase II, including long-term extension data (ICPT 2013 10-K) - POISE - Accelerated Approval in PBC and surrogates of transplant-free survival - Will one study be enough? - In summary 2. Non-alcoholic steatohepatitis (NASH) - NAFLD and NASHa brief review - Phase II study in diabetic NAFLD - The FLINT study - Endpoint issues and approval pathways for NASH - Update on lipid changes in phase II studies of fatty liver 3. Update on other indications 4. Summary opinion - PBC - NASH - Other indications Companies Mentioned - Albireo - Antipodean Pharmaceuticals - Intercept Pharmaceuticals - Johnson & Johnson - Kotobuki Pharmaceuticals - NovImmune - Phenex For more information visit http://www.researchandmarkets.com/research/bfcxg8/intercept About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Dow Inches Higher As Travelers Hits New All-Time High; J&J, Pfizer Also Gain
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 22, 8:05PM CDT
On Thursday, the Dow Jones Industrials gained 10 points, lagging behind the percentage gains in the broader market but still adding to its triple-digit advance from Wednesday. Investors seemed content to ride the ongoing wave of optimism higher,...
